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Aim: To assess control and morbidity in patients with type 1 diabetes mellitus (T1 attending a tertiary adult diabetes clinic in
Durban, South Africa.
Methods: A retrospective chart review of all patients with T1D who attended clinic in the years 2006, 2012 and 2015. Clinical and
laboratory changes were assessed at an individual patient-level follow-up (IPLF) and whole clinic level (n = 231).
Results: In the IPLF study arm (n = 58; 45% Black patients; 62% female; median age 18 years), mean HbA1c [% (mmol/mol)]
decreased from 9.9 ± 2.6% (85 ± 28) in 2006 to 8.7 ± 1.5% (72 ± 16) in 2012 (p < 0.001) and to 9.1 ± 1.7% (76 ± 19) in 2015
(p = 0.03); target HbA1c < 7.0% (< 53 mmol/mol) was achieved in 7.1%, 5.3% and 8.3%, respectively. Compared with 2006, in
2015 there was a higher prevalence of retinopathy (10.3% vs. 29.3%, p = 0.004), abnormal glomerular filtration rate (0% vs.
6.9%, p = 0.04) and abnormal serum creatinine (0% vs. 8.6%, p = 0.02). Predictive risk factors for new retinopathy included
diabetes duration (OR 1.4; 95% CI 1.0–1.3; p = 0.03) and diastolic blood pressure (OR 1.15; 95% CI 1.0–1.3; p = 0.04).
Conclusion: Glycaemic control improved over 10 years, but fell short of recommended targets. Intensive efforts are required to
achieve current targets for glycaemic and non-glycaemic control.
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Introduction
The Diabetes Control and Complications Trial (DCCT) established
that the risk of microvascular complications (new retinopathy,
albuminuria and neuropathy) in subjects with type 1 diabetes
(T1D) was significantly reduced with intensive therapy (IT)
(median HbA1c 7.2%; 55 mmol/mol), compared with conven-
tional treatment (CT), (median HbA1c 9.1%; 76 mmol/mol).1
The DCCT findings supported the improved outcome with
better glycaemic control in T1D shown in earlier studies.2–4 In
the follow-up study to the DCCT, the Epidemiology of Diabetes
Interventions and Complications (EDIC) trial, despite the differ-
ence in HbA1c being negligible between the two groups by
year five, the original IT group had a lower risk of micro- and
macro-vascular complications as long as 18 years after the com-
mencement of EDIC (and 28 years after starting the DCCT).5,6
This supported the concept of metabolic memory/legacy
effect and the long-term benefit of stringent glycaemic
control. This was confirmed in a recent systematic review and
meta-analysis of 12 studies, which showed that when compared
with CT, IT had a significantly lower risk of developing retinopa-
thy (6.2 vs. 23.2%), nephropathy (16.3 vs. 28.4%) and neuropathy
(4.9 vs. 13.9%).7
Glycaemic targets vary according to age and clinical circum-
stances. The International Society of Paediatric and Adolescent
Diabetes (ISPAD) guidelines recommend a target HbA1c of less
than 7.5% (58 mmol/mol) for children and adolescents.8 In
adults with T2D, the Society of Endocrinology, Metabolism and
Diabetes of South Africa (SEMDSA) and the American Diabetes
Association (ADA) recommend a target HbA1c of < 7.0%
(< 53 mmol/mol) for most patients; a more stringent target of
< 6.5% (< 48 mmol/mol) can be considered in young patients
with no co-morbidities, while a range of 7.1–8.5% (54–
69 mmol/mol) is advised for older patients with multiple co-mor-
bidities.9,10 Despite these published guidelines, the glycaemic
goals are seldom achieved. In the United States only 21% of
patients between the ages of 13 and 20 years with T1D attained
an HbA1c below 7.5% (58 mmol/mol).11 A meta-analysis of eight
studies showed that only 27.2% of patients with T1D achieved
an HbA1c of less than 7% (53 mmol/mol).12 In South Africa, a
study of 198 patients with T1D managed in private healthcare
reported a mean HbA1c of 8.8% (73 mmol/mol).13 Implemen-
tation of an education and monitoring programme for patients
with T1D in Rwanda between 2009 and 2012 achieved a
reduction in HbA1c from 11.2% (99 mmol/mol) to 9.8%
(84 mmol/mol) over a two-year period, but this still failed to
meet international HbA1c recommendations.14
Available reports on trends in glycaemic control and dia-
betes complications in patients with T1D are variable. A
Japanese study showed a moderate decrease in HbA1c
from 7.91% (63 mmol/mol) to 7.68% (61 mmol/mol), and a
lower prevalence of nephropathy and retinopathy in two
cohorts recruited 10 years apart. A Swedish study found
that the 25-year incidence of nephropathy and retinopathy
was lower in patients who were diagnosed with T1D 10
years later.15,16 By contrast, a similar study in the USA
failed to show this trend.17
Abbreviations: ACR: albumin creatinine ratio; ADA: American Diabetes Association; BMI: body mass index; BP: blood pressure; CL: clinic level; CT: con-
ventional treatment; DCCT: the Diabetes Control and Complication Trial; DKA: diabetes ketoacidosis; EDIC: the Epidemiology of Diabetes Interventions
and Complications; GAD: glutamic acid decarboxylase; GFR: glomerular filtration rate; IA2: islet antigen 2; IALCH: Inkosi Albert Luthuli Central Hospital;
GFR: estimated glomerular filtration rate; iGFR: isotope glomerular filtration rate; HDL: high density lipoprotein; IPLF: individual patient-level follow-up;
ISPAD: International Society of Paediatric and Adolescent Diabetes; IT: intensive therapy; LDL: low density lipoprotein; MACE: major adverse cardiovas-
cular event; T1D: type 1 diabetes; TC: total cholesterol
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There are no studies showing trends in glycaemic control and
patterns of diabetes complications in patients with T1D
treated in public health facilities in South Africa. The current
study was undertaken to re-evaluate the management of T1D;
specifically, to assess trends in the control of glycaemic and
non-glycaemic parameters over time, and to determine rates
of vascular complications.
Subjects, materials and methods
Variables
This study was a retrospective chart review of all patients with
T1D who attended the adult diabetes clinic at Inkosi Albert
Luthuli Central Hospital (IALCH) in Durban, KwaZulu-Natal, at
three time-points over a 10-year period (January 2006 to
December 2015). IALCH is a tertiary referral hospital for the
province of KwaZulu-Natal in South Africa and offers a dia-
betes management service at specialist and sub-specialist
levels. The study was approved by the University of
KwaZulu-Natal Biomedical Research Ethics Committee (refer-
ence number BE 417/17).
The study comprised two arms: the first arm included patients
with T1D who had attended the clinic in all 3 years of review
(2006, 2012 and 2015) to assess trends at an individual patient
level—the individual patient-level follow-up study (IPLF). The
second arm included all patients with T1D who attended the
clinic in the years 2006 and 2015—clinic-level (CL) arm. Since
some patients had left the clinic, while new patients had
joined during this period, the determination of trends in this
study was at the clinic level. The electronic health record (EHR)
system at IALCH was used to identify patients and data were
also extracted from individual computer files for the first visit
in each study year.
Demographic data collected included age, duration of dia-
betes, ethnic group and gender; anthropometric measures
included weight, height and body mass index. The mode of
presentation of diabetes was recorded as asymptomatic detec-
tion, symptomatic hyperglycaemia or diabetic ketoacidosis
(DKA). Presence or absence of anti-glutamic acid decarboxy-
lase (GAD) and anti-islet antigen 2 (IA2) antibodies, as well
as fasting and post-glucagon stimulation c-peptide values,
were recorded. Parameters of glycaemic control included
random plasma glucose, HbA1c and serum fructosamine;
non-glycaemic parameters included blood pressure, serum
creatinine, serum lipids, urine dipstick, spot random urine
albumin creatinine ratio (ACR) for microalbuminuria, estimated
glomerular filtration rate (eGFR) and isotope glomerular fil-
tration rate (iGFR). Complications of diabetes were recorded,
including nephropathy, retinopathy, and major adverse cardio-
vascular events (MACE).
Laboratory methods
Laboratory tests were undertaken by the National Health Lab-
oratory Services (NHLS) at IALCH. HbA1c was measured by
high performance liquid chromatography (HPLC) (Tosoh®) and
fructosamine by calorimetric assay (Roche Modular). Anti-GAD
and anti-IA2 were analysed by ELISA (Euroimmune) and c-
peptide by chemiluminescent assay (Roche Elecsys). Serum
lipids were measured by enzymatic reaction (Siemens Advia).
Isotope glomerular filtration rate (iGFR) was measured
with a multi-channel well counter and blood analysis at 2
and 3 hours post-injection of 500 μCi 99mTc-DTPA
(diethylenetriamine pentaacetate).18 Estimated glomerular
filtration rate (eGFR) was calculated using the Chronic Kidney
Disease Epidemiology Collaboration Equation.19
Definitions
T1D was diagnosed if, at the time of diagnosis, patients had
two or more of the following: presentation with diabetic
ketoacidosis (DKA), positive anti-GAD or anti-IA2 antibodies,
fasting c-peptide < 0.75 ng/ml, glucagon-stimulated c-peptide
< 1.8 ng/ml, or absolute insulin dependence.20,21 Anti-GAD
and anti-IA2 antibodies were deemed positive if the titre was
≥ 10 IU/ml. Nephropathy was diagnosed if the spot
urine ACR≥ 3.0 mg/mmol: microalbuminuria if ACR was
3–30 mg/mmol and proteinuria if ACR≥ 30 mg/mmol or a
urine dipstick was positive for protein. Abnormal GFR was
defined if < 60 ml/min/m2 (normal reference range 95–
123 ml/min/m2 for females and 98–150 ml/min/m2 for males).
Abnormal serum creatinine was defined if > 104 µmol/l for
males and > 84 µmol/l for females.22 Hypertension was diag-
nosed if systolic blood pressure was≥ 140mmHg or diastolic
blood pressure was≥ 90 mmHg.23 Retinopathy was assessed
by fundal photography and defined by the presence of microa-
neurysms, exudates, bleeds, retinal ischemia or macular oedema
(non-proliferative); or retinal neovascularisation (proliferative).24
A major adverse cardiovascular event (MACE) included a fatal or
nonfatal myocardial infarction, coronary re-vascularisation or
cerebrovascular accident.25
Data analysis
Data were analysed using Stata (version 13; StataCorp, College
Station, TX, USA). Descriptive statistics were used to summarise
the data. Frequencies and percentages were used for categorical
data. Numeric data were checked for normality and parametric
(means [SD]) or non-parametric (medians [IQR]) method used.
Comparisons between the three years in the IPLF study were
undertaken using ANOVA, paired t-test or Wilcoxon signed-
rank test for continuous variables and McNemar’s chi-square
test for categorical variables. To assess risk factors for develop-
ment of retinopathy, in bivariate analysis, the baseline character-
istics (2006) of the group that developed retinopathy by 2015
were compared with the group that did not. Logistic regression
analysis was undertaken to determine the significant risk factors
(predictors) for future retinopathy. The magnitude of risk ratio is
presented as the odds ratio (OR) with 95% confidence interval
(CI) and p-value.
Comparison between the two years in the clinic-level (CL) study
was done using Dunn’s pairwise comparison with Sidak adjust-
ment for continuous variables, and Pearson’s chi-square test or
Fisher’s exact test for categorical variables. A p-value of < 0.05
was considered statistically significant.
Results
The IPLF arm followed the same 58 patients in 2006, 2012 and
2015, while the CL arm included 132 patients in 2006 and 231
patients in 2015.
Individual patient level follow-up (IPLF) study
This arm included 58 patients (60.1% female) who attended the
clinic in all three years of analysis (2006, 2012 and 2015).
Baseline demographic characteristics are given in Table 1. The
majority (93%) of patients were Asian Indian (n = 28, 48.3%)
and African (Black) (n = 26;44.8%); the remainder included 3
(5.2%) White and 1 (1.7%) mixed-race (Coloured) patients. In
2006 the median age was 30 (21–36) years, age at diagnosis
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was 18 (13–22) years and the duration of diabetes was 12 (6–19)
years. Most patients (44.8%) presented with symptomatic hyper-
glycaemia, and 17 (29.3%) presented with DKA. Median BMI
(kg/m2) increased significantly from 24.6 (22–28) in 2006 to
27.5 (24–31) in 2012 (p = 0.001). Anti-GAD was positive in
64.9% (n = 37). In 26 patients with available c-peptide results,
cut-off points for T1D definition were met in 88.5% for fasting
value, and 92.3% for glucagon-stimulated level.
Glycaemic and non-glycaemic parameters
Table 1, and Figures 1 and 2 show clinical and laboratory vari-
ables for the IPLF group. Mean HbA1c (SD) decreased signifi-
cantly from 9.9 (2.6)% (85 (28) mmol/mol) in 2006 to 8.7 (1.5)%
(72 (16) mmol/mol) in 2012 (p < 0.001); by 2015, HbA1c had
increased to 9.1 (1.7)% (76 (19) mmol/mol) but remained sig-
nificantly lower than at baseline (2006) (p = 0.03). The proportion
of patients who achieved a target HbA1c < 7.0% (< 53 mmol/mol)
was low and showed no significant difference at the three
time points (7.1% vs. 5.3% vs. 8.8%, p = 0.36). Median serum
fructosamine was not measured in 2006 and showed no
significant change from 2012 to 2015 (356 [IQR 315–389] vs.
361 [322–414] µmol/l).
Median total cholesterol (TC) and LDL cholesterol (LDL-C) fol-
lowed a similar pattern to HbA1c, with a significant decrease
from 2006 to 2012, and a non-significant increase from 2012
to 2015. When compared with 2006, median HDL was signifi-
cantly lower in 2012 and 2015 (p = <0.01 for both). The pro-
portion of patients on statin therapy increased from 19% in
2006 to 39.7% in 2015 (p = 0.001).
Median systolic blood pressure increased from 2006 to 2015
(p = 0.002) and median diastolic blood pressure decreased
from 2006 to 2012 (p = 0.004), then increased in 2015










African (Black) 44.8 (26) – –
Indian 48.3 (28) – –
White 5.2 (3) – –
Mixed race 1.7 (1) – –
Gender (m:f) (n) 22:36 – –
Age (years) 30 (21–36) – –
Age at diagnosis (years) 18 (13–22) – –
Diabetes duration (years) 12 (6–19) 17 (12–23) 20 (15–26)
Presentation:
Ketoacidosis 29.3 (17) – –
Symptomatic 44.8 (26) – –
High glucose 13.8 (8) – –
Unknown 10.3 (6) – –
BMI (kg/m2) 24.6 (22–28) 27.5 (24–31)c 26.6 (24–30)c
Systolic BP (mmHg) 121 (110–131) 128 (110–131)b 129 (119–138)b
Diastolic BP (mmHg) 74 (69–81) 69 (61–79)b,d 76 (68–81)
Anti-GAD positive* 64.9 (37) – –
HbA1c (%), mean (SD)† 9.9 (2.6) 8.7 (1.5)c,d 9.1 (1.7)a
(mmol/mol)† 85 (28) 72 (16)c,d 76 (19)a
Serum lipids(mmol/l):
Total cholesterol 4.7 (4.2–5.4) 4.2 (4.0–5.0)a 4.5 (4.0–5.0)
LDL cholesterol 2.4 (1.9–3.0) 2.1 (1.9–2.5)c 2.2 (1.9–2.7)b
HDL cholesterol 1.6 (1.3–2.0) 1.5 (1.3–1.8)c 1.5 (1.2–1.9)b
Triglycerides 1.2 (0.7–1.9) 1.1 (0.8–1.7) 1.0 (0.7–1.5)
iGFR (ml/min/m2) 113 (98–128) 111 (92–126) 97 (82–124)b
eGFR(ml/min/1.73m2) 124(105–136) 116(101–134)b 117(93–131)b
Serum creatinine(µmol/l) 66(57–79) 65(56–75) 61(53–78)
Urine albumin/creatinine ratio: 1.2(0.6–2.6) 2.0(0.9–6.1) 1.0(0.4–4)
3–30 mg/mmol 19 (11) 34.5 (20) 22.4 (13)
>30 mg/mmol 15.5 (9) 13.8 (8) 5.2 (3)
≥3 mg/mmol 34.5(20) 48.3 (28) 27.6 (16)
Data shown as % (n), median (IQR) or mean (SD).
*N = 56 (2 missing values). †N = 57 (1 missing value).
BMI: body mass index; BP: blood pressure; GAD: glutamic acid decarboxylase; iGFR: isotope glomerular filtration rate; eGFR: estimated glomerular filtration rate; LDL: low
density lipoprotein; HDL: high density lipoprotein.
P-values are for comparisons between the three groups by ANOVA, paired t-test or Wilcoxon signed-rank test for pairs of continuous variables and McNemar’s chi-square test
for pairs of categorical variables.
ap < 0.05, bp < 0.01, cp < 0.001 vs. 2006, dp < 0.05 vs. 2015.
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*N = 56 (2 missing values). †N = 57 (1 missing value).
BMI: body mass index; BP: blood pressure; GAD: glutamic acid decarboxylase; iGFR: isotope glomerular filtration rate; eGFR: estimated glomerular filtration rate; LDL: low
density lipoprotein; HDL: high density lipoprotein.
P-values are for comparisons between the three groups by ANOVA, paired t-test or Wilcoxon signed-rank test for pairs of continuous variables and McNemar’s chi-square test
for pairs of categorical variables.
ap < 0.05, bp < 0.01, cp < 0.001 vs. 2006, dp < 0.05 vs. 2015.
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(p = 0.002 vs. 2012). Although the prevalence of diagnosed
hypertension increased from 2006 to 2015 (31% vs. 46.6%),
there was no significant difference. Both median iGFR
(113 [98–128] vs. 97 [82–124] ml/min/m2, p= 0.009) and median
eGFR (124 [105–136] vs. 117 [93–131] ml/min/m2, p = 0.009)
decreased from 2006 to 2015.
Microvascular and macrovascular complications
Table 1 and Figure 2 show the prevalence of chronic compli-
cations for the study years. In 2006 the prevalence of retinopathy
was 10.3% and by 2015 this had increased to 29.3%. The pro-
portion of patients with microalbuminuria or proteinuria did not
change significantly. While the prevalence of abnormal iGFR
increased from no patients in 2006 to four patients (6.9%) in
2015 (p = 0.04), abnormal eGFR did not increase significantly
(0% vs 5.2%). Abnormal serum creatinine which was not observed
in any patient in 2006 was found in five patients (8.6%) by 2015
(p = 0.02). MACE was infrequent and documented in only one
patient in 2006 and one additional patient in 2015.
Risk factors for retinopathy
Of 52 patients who did not have retinopathy in 2006, 11 patients
(21.2%) developed new retinopathy by 2015. Table 2 indicates
the baseline (2006) characteristics and analysis of risk factors
for new retinopathy development by 2015, in the 52 patients
who were retinopathy free in 2006. In bivariate analysis,
when compared with patients who did not develop retinopathy
(n = 41), patients who developed retinopathy had significantly
longer duration of diabetes, higher diastolic blood pressure
and lower prevalence of positive anti-GAD. In regression analy-
sis, significant predictive risk factors included diabetes duration
(OR 1.4; 95% CI 1.0–1.3; p = 0.03) and diastolic blood pressure
(OR 1.15; 95% CI 1.0–1.3; p = 0.04), while a positive anti-GAD
was protective (OR 0.05; 95% CI 0.01–0.4; p = 0.01). An increase
of 10 years in duration of T1D increased the risk of retinopathy
by 3.8, and a rise of 10 mmHg in diastolic blood pressure
increased the risk by 4.1.
Clinic Level (CL) Study
The CL study arm included 132 patients who attended the clinic
in 2006 and 231 patients who attended in 2015.
Table 3 shows the clinical characteristics at 2006 and 2015. At
both time points, African (Black) subjects predominated (50%
in 2006 and 57.6% in 2015), followed by Asian Indians (43.2%
in 2006 and 29.9% in 2015) and small numbers of White and
mixed-race (Coloured) patients. Although the median age at dia-
betes diagnosis was significantly lower in 2015 (16 [12–22] years)
than in 2006 (13 [10–20] years) (p = 0.001), the duration of dia-
betes was equal (9 [5–15] vs. 9 [4–16] years, p = 0.79). In 2006,
the presentation was predominantly with symptomatic hyper-
glycaemia (50%), whereas in 2015, the most common presen-
tation was DKA (43.3%).
Glycaemic and non-glycaemic parameters
Table 3 displays the clinical and laboratory variables for the
CL group. There was no significant change in mean HbA1c
(SD) from 2006 to 2015 (10.8 [2.9] vs. 10.2 [2.5]%; 95 [32] vs.
88 [28] mmol/mol; p = 0.22). The proportion who achieved an
HbA1c of < 7.0% (< 53 mmol/mol) was low and did not
change significantly from 2006 (5.4%) to 2015 (5.2%). Median
systolic blood pressure was higher in 2015 compared with
2006 (126 [117–137] vs. 120 [107–131] mmHg, p < 0.001).
Serum total cholesterol and HDL cholesterol were significantly
lower in 2015 than in 2006 (p = 0.001). The proportion of
patients treated with statins and anti-hypertensive agents was
similar in both years.
Microvascular and macrovascular complications
The prevalence of retinopathy did not change from 2006 (15.2%)
to 2015 (15.6%). When compared with 2006, the proportion of
patients with microalbuminuria was significantly higher in
2015 (18.9% vs. 22.5%, p < 0.001), while that of proteinuria
was lower (20.5% vs 8.2%, p = 0.001). The median iGFR,
prevalence of abnormal iGFR and creatinine was similar in
2006 and 2015, as was the prevalence of MACE (Table 3).
Discussion
This retrospective study on diabetes control and complications
over a 10-year period has shown that at the individual patient
level glycaemic control improved, but at an overall clinic level
there was no significant change. In both arms of the study, the
proportion of patients achieving a target HbA1c < 7.0%
(< 53 mmol/mol) did not improve significantly. Significant risk
factors for development of new retinopathy included diabetes
duration and diastolic blood pressure.
The improvement in glycaemic control shown in the IPLF study
arm is probably accounted for by a number of interventions that
were introduced to the clinic after 2006. These included the ser-
vices of a diabetes nurse educator, development and
Figure 1: Glycaemic and non-glycaemic parameters in the individual-
patient-level follow-up (IPLF) study group (n = 58) according to study
year. P-values are for comparisons between the three groups by McNe-
mar’s chi-square test for pairs of categorical variables. ap < 0.01, bp <
0.001 vs. 2006.
Figure 2: Chronic complications in the individual-patient-level follow-up
(IPLF) study (n = 58) according to study year. ACR: albumin creatinine
ratio; iGFR: isotope glomerular filtration rate; eGFR: estimated glomerular
filtration rate; MACE: major adverse cardiovascular event; p-values are for
comparisons between the three groups by McNemar’s chi-square test for
pairs of categorical variables. ap < 0.05, bp < 0.01 vs. 2006.
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dissemination of a written manual on self-management, and
improvement in assessment of home glucose monitoring profiles,
with the use of computer downloads of patient meters. The lack
of a significant change in HbA1c in the clinic-level study between
2006 and 2015 is probably explained by the mixed group, with
overall improvements being diluted by new patients (with
poorer glycaemic control) entering the clinic. This suggests that
a number of years of attendance at a specialist clinic is required
to improve glycaemic control in this environment.
Despite the improvement in glycaemic control in the IPLF group,
the mean values still exceeded the ISPAD and ADA recommen-
dations of 7.5% (58 mmol/mol) and 7.0% (53 mmol/mol),
respectively,8,10 with only 8.8% achieving an HbA1c < 7.0%
(< 53 mmol/mol) by 2015. This finding is not unique to the
present study. A study on a real-world experience of glycaemic
control in T1D showed that attainment of optimal HbA1c
occurred in less than a third of patients.12 Using data from
national or regional registries on 324,501 patients with T1D
from 19 countries in Europe and Oceania, McKnight et al.
reported wide variation in glycaemic control between centres,
with median HbA1c in the group aged > 25 years ranging
from 7.4 (6.7–8.3)% (57 [50–67] mmol/mol) to 8.5 (7.7–9.5)%
(69 [61–80] mmol/mol). The proportions with HbA1c < 7.5%
(58 mmol/mol) varied from 15.7% to 46.4% in patients aged
< 15 years, from 8.9% to 49.5% in patients aged 15–24 years,
and from 20.5% to 53.6% in people aged≥ 25 years.26 A more
recent report, using general-practice-level data from the
United Kingdom National Diabetes Audit for the years 2013–
2016, found that 54.9% of subjects with T1D had an HbA1c
between 7.5 and 10% (58–86 mmol/mol) and 15.9% had an
HbA1c > 10% (86 mmol/mol); there was also a wide variation
in patients achieving target glycaemic control (HbA1c < 7.5%;
<58 mmol/mol), ranging from 15.6% to 44.8%.27
There are limited data on glycaemic control in diabetes in
developing countries in Africa. A study on 198 patients with
T1D conducted in the private healthcare system in South
Africa reported a median HbA1c of 8.8% (73 mmol/mol)13 and
a study in Rwanda showed a reduction in HbA1c from 11.2%
(99 mmol/mol) to 9.8% (84 mmol/mol) between 2009 and
2012.14 However, neither of these studies documented the pro-
portion of patients who achieved a target HbA1c for good gly-
caemic control. These limited data reflect overall poor
glycaemic control in patients with T1D in developing countries
and indicate the need for substantial investment in strategies
to improve the situation.
The IPLF arm showed that the trends in medium serum TC and
LDL-C mirrored that for HbA1c, falling from 2006 to 2012, fol-
lowed by an increase in 2015. In addition, the proportion of
patients on statin therapy more than doubled from 2006
(19%) to 2015 (39.7%). This underscores the relationship
between glycaemic control and serum lipids.28 Such findings
may indicate that the duration of diabetes and age are risk
factors for dyslipidaemia or may reflect better implementation
Table 2: Baseline (2006) characteristics and analysis of risk factors for retinopathy development in the individual-patient-level follow-up (IPLF) study







n = 11 OR 95% CI p
Ethnicity:
Black (n = 22) 82 (18) 18 (4)
Indian (n = 26) 81 (21) 19 (5)
Other (n = 4) 50 (2) 50 (2)
Sex (M:F) (n) 17:24 3:8
Age (years) 29.3 (20–36) 36.2 (29–41)
Diabetes duration (years) 10.9 (5–14) 17.7 (13.5–24)* 1.14 1.0–1.3 0.03
Anti-GAD positive (%) 91 (3) 9 (3)* 0.05 0.01–0.4 0.01
Hypertension (%) 71 (10) 29 (4)
BMI (kg/m2) 24.9 (22.6–27.6) 26.6 (23.4–30)
Systolic BP (mmHg) 120 (110–130) 125 (112–132)
Diastolic BP (mmHg) 73 (67–80) 79 (73–86)* 1.15 1.0–1.3 0.04
HbA1c (%) 9.62 (2.8) 10.1 (1.8)
(mmol/mol) 81 (31) 87 (12)
Serum lipids(mmol/l)
Total cholesterol 4.72 (3.98–5.18) 5.19 (4.55–5.6)
LDL 2.41 (1.93–2.7) 2.87 (2.35–3.35)
Triglycerides 1.22 (0.58–1.86) 1.74 (1.31–1.98)
HDL 1.72 (1.39–2.03) 1.71 (1.35–2.05)
iGFR (ml/min/m2) 114 (99–127) 109 (84–132)
Data shown as % (n), median (IQR) or mean (SD).
*p < 0.05.
BMI: body mass index; BP: blood pressure; iGFR: isotope glomerular filtration rate; eGFR: estimated glomerular filtration rate; GAD: glutamic acid decarboxylase; LDL: low
density lipoprotein; HDL: high density lipoprotein.
P-values are for comparisons between the two groups by Wilcoxon signed-rank test for pairs of continuous variables and McNemar’s chi-square test for pairs of categorical
variables.
The magnitude of risk ratio is presented as the odds ratio (OR) with 95% confidence interval (CI) and p-value.
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dissemination of a written manual on self-management, and
improvement in assessment of home glucose monitoring profiles,
with the use of computer downloads of patient meters. The lack
of a significant change in HbA1c in the clinic-level study between
2006 and 2015 is probably explained by the mixed group, with
overall improvements being diluted by new patients (with
poorer glycaemic control) entering the clinic. This suggests that
a number of years of attendance at a specialist clinic is required
to improve glycaemic control in this environment.
Despite the improvement in glycaemic control in the IPLF group,
the mean values still exceeded the ISPAD and ADA recommen-
dations of 7.5% (58 mmol/mol) and 7.0% (53 mmol/mol),
respectively,8,10 with only 8.8% achieving an HbA1c < 7.0%
(< 53 mmol/mol) by 2015. This finding is not unique to the
present study. A study on a real-world experience of glycaemic
control in T1D showed that attainment of optimal HbA1c
occurred in less than a third of patients.12 Using data from
national or regional registries on 324,501 patients with T1D
from 19 countries in Europe and Oceania, McKnight et al.
reported wide variation in glycaemic control between centres,
with median HbA1c in the group aged > 25 years ranging
from 7.4 (6.7–8.3)% (57 [50–67] mmol/mol) to 8.5 (7.7–9.5)%
(69 [61–80] mmol/mol). The proportions with HbA1c < 7.5%
(58 mmol/mol) varied from 15.7% to 46.4% in patients aged
< 15 years, from 8.9% to 49.5% in patients aged 15–24 years,
and from 20.5% to 53.6% in people aged≥ 25 years.26 A more
recent report, using general-practice-level data from the
United Kingdom National Diabetes Audit for the years 2013–
2016, found that 54.9% of subjects with T1D had an HbA1c
between 7.5 and 10% (58–86 mmol/mol) and 15.9% had an
HbA1c > 10% (86 mmol/mol); there was also a wide variation
in patients achieving target glycaemic control (HbA1c < 7.5%;
<58 mmol/mol), ranging from 15.6% to 44.8%.27
There are limited data on glycaemic control in diabetes in
developing countries in Africa. A study on 198 patients with
T1D conducted in the private healthcare system in South
Africa reported a median HbA1c of 8.8% (73 mmol/mol)13 and
a study in Rwanda showed a reduction in HbA1c from 11.2%
(99 mmol/mol) to 9.8% (84 mmol/mol) between 2009 and
2012.14 However, neither of these studies documented the pro-
portion of patients who achieved a target HbA1c for good gly-
caemic control. These limited data reflect overall poor
glycaemic control in patients with T1D in developing countries
and indicate the need for substantial investment in strategies
to improve the situation.
The IPLF arm showed that the trends in medium serum TC and
LDL-C mirrored that for HbA1c, falling from 2006 to 2012, fol-
lowed by an increase in 2015. In addition, the proportion of
patients on statin therapy more than doubled from 2006
(19%) to 2015 (39.7%). This underscores the relationship
between glycaemic control and serum lipids.28 Such findings
may indicate that the duration of diabetes and age are risk
factors for dyslipidaemia or may reflect better implementation
Table 2: Baseline (2006) characteristics and analysis of risk factors for retinopathy development in the individual-patient-level follow-up (IPLF) study







n = 11 OR 95% CI p
Ethnicity:
Black (n = 22) 82 (18) 18 (4)
Indian (n = 26) 81 (21) 19 (5)
Other (n = 4) 50 (2) 50 (2)
Sex (M:F) (n) 17:24 3:8
Age (years) 29.3 (20–36) 36.2 (29–41)
Diabetes duration (years) 10.9 (5–14) 17.7 (13.5–24)* 1.14 1.0–1.3 0.03
Anti-GAD positive (%) 91 (3) 9 (3)* 0.05 0.01–0.4 0.01
Hypertension (%) 71 (10) 29 (4)
BMI (kg/m2) 24.9 (22.6–27.6) 26.6 (23.4–30)
Systolic BP (mmHg) 120 (110–130) 125 (112–132)
Diastolic BP (mmHg) 73 (67–80) 79 (73–86)* 1.15 1.0–1.3 0.04
HbA1c (%) 9.62 (2.8) 10.1 (1.8)
(mmol/mol) 81 (31) 87 (12)
Serum lipids(mmol/l)
Total cholesterol 4.72 (3.98–5.18) 5.19 (4.55–5.6)
LDL 2.41 (1.93–2.7) 2.87 (2.35–3.35)
Triglycerides 1.22 (0.58–1.86) 1.74 (1.31–1.98)
HDL 1.72 (1.39–2.03) 1.71 (1.35–2.05)
iGFR (ml/min/m2) 114 (99–127) 109 (84–132)
Data shown as % (n), median (IQR) or mean (SD).
*p < 0.05.
BMI: body mass index; BP: blood pressure; iGFR: isotope glomerular filtration rate; eGFR: estimated glomerular filtration rate; GAD: glutamic acid decarboxylase; LDL: low
density lipoprotein; HDL: high density lipoprotein.
P-values are for comparisons between the two groups by Wilcoxon signed-rank test for pairs of continuous variables and McNemar’s chi-square test for pairs of categorical
variables.
The magnitude of risk ratio is presented as the odds ratio (OR) with 95% confidence interval (CI) and p-value.
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of international guidelines for lipid management in diabetes. The
proportion on statin therapy in the CL arm in 2015 (15.6%) was
higher than patients with T1D in the Swedish national registry
(10.7%),29 but much lower than that reported in a Danish study
(43.5%);30 in the latter study, statin users were older, with
longer diabetes duration and more severe kidney disease.
Systolic and diastolic blood pressure, and the proportion of
patients on antihypertensive medication increased significantly
from 2006 to 2015 in the IPLF study; by 2015, the prevalence
of hypertension (46.6%) was higher (46.6% vs. 31%) but had
not increased significantly. The higher prevalence may be due
to increased age. The prevalence in 2015 is higher than that
reported in other larger studies on adults with T1D (19.2–
43%).31–33 This may be due to the high proportion of African
patients, who have an increased risk of hypertension compared
with Caucasians and Asians.34 The increase in antihypertensive
medication use (37.9% to 63.8%) from 2006 to 2015 included
27% of the cohort who received ACE inhibitors to lower urine
protein excretion.
The 10-year incidence of retinopathy in the IPLF group was
21.2%. This was lower than the nine-year incidence in a
Spanish study (47.3%),35 but similar to a large study in the
USA with a median follow-up period of 3.2 years, which
showed an incidence of 20.1% amongst patients diagnosed
with diabetes aged under 21 years.36 Significant risk factors
identified for the development of new diabetic retinopathy in





n = 231 p-value
Ethnicity: 0.03
African 50 (66) 57.6 (133)
Indian 43.2 (57) 29.9 (69)
White 4.5 (6) 4.8 (11)
Mixed race 2.3 (3) 7.8 (18)
Gender: 0.94
Male 45.5 (60) 45.9 (106)
Female 54.5 (72) 54.1 (125)
Age (years) 27 (20–36) 22 (18–33) 0.02
Age at diagnosis (years) 16 (12–22) 13 (10–20) 0.001
Diabetes duration (years) 9 (5–15) 9 (4–16) 0.79
Presentation: 0.05
Ketoacidosis 32.6 (43) 43.3 (100)
Symptomatic 50 (66) 40.3 (93)
Abnormal glucose 10.6 (14) 6.1 (14)
Unknown 6.8 (9) 10.4 (24)
Anti-GAD positive* 58.2 (53) 72.1(163) 0.016
BMI (kg/m2) 24.6 (21–28) 24.5 (21–28) 0.84
Systolic BP (mmHg) 120 (107–131) 126 (117–137) < 0.001
Diastolic BP (mmHg) 74 (68–81) 75 (68–83) 0.37
HbA1c (%)† 10.8 (2.9) 10.2 (2.5) 0.22
(mmol/mol)† 95 (32) 88 (28) 0.22
Serum lipids (mmol/l):
Total cholesterol 4.8 (4.0–5.4) 4.3 (3.8–5.0) 0.001
LDL cholesterol 2.4 (1.9–3.0) 2.3 (1.8–2.8) 0.22
HDL cholesterol 1.7 (1.3–2.0) 1.4 (1.2–1.8) < 0.001
Triglycerides 1.0 (0.7–1.7) 0.9 (0.6–1.4) 0.08
iGFR (ml/min/m2) 111(90–129) 115(96–136) 0.17
Serum creatinine (µmol/l) 70 (58–82) 59 (50–73) 0.41
Urine albumin/creatinine ratio:‡ 1.2(0.5–3.3) 1.1 (0.4–4.4) 0.02
3–30 mg/mmol 18.9 (25) 22.5 (52) < 0.001
> 30 mg/mmol 20.5 (27) 8.2 (19) 0.001
≥ 3 mg/mmol 39.7(52) 31.0 (71) 0.09
Retinopathy 15.2 (20) 15.6 (36) 0.99
MACE 1.5 (2) 2.2 (5) 0.99
Data shown as % (n), median (IQR) or mean (SD).
*n = 91 in 2006, n = 226 in 2015.
†n = 131 in 2006, n = 230 in 2015.
‡n = 129 in 2006, n = 229 in 2015.
BMI: body mass index; BP: blood pressure; iGFR: isotope glomerular filtration rate; eGFR: estimated glomerular filtration rate; GAD: glutamic acid decarboxylase; LDL: low
density lipoprotein; HDL: high density lipoprotein; MACE: major adverse cardiovascular event.
P-values are for comparisons between the two groups by Dunn’s pairwise comparison with Sidak adjustment for continuous variables and Pearson’s chi-square or Fisher’s
exact test for categorical variables.
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the current study included duration of T1D and diastolic blood
pressure, while a positive anti-GAD was protective. This confirms
reports from other studies, which also found that increased dias-
tolic blood pressure and diabetes duration were predictors of
diabetic retinopathy.35–38 In the DCCT/EDIC trial, which ident-
ified diastolic BP as a risk factor, only 3% had hypertension at
baseline.37 The other studies do not mention the baseline
blood pressure, or the proportion diagnosed with hypertension.
To our knowledge there are no studies that reported anti-GAD
positivity being protective and the relevance of this finding is
unclear and requires further investigation.
The higher iGFR seen in 2006 in the IPLF arm may be explained
by hyperfiltration seen in stage 1 diabetic nephropathy. The 10-
year incidence of abnormal iGFR (6.9%) is comparable to an
Italian study,39 but was significantly higher than both the inten-
sive and conventional therapy arms of the DCCT/EDIC trial (20-
year incidence of 2% and 5.5%, respectively).40 By 2015 there
was a wide discrepancy between median iGFR and eGFR
(97 [82–124] vs. 117 [93–131]). This may indicate that the eGFR
is an overestimate.
The prevalence of macrovascular disease was lower than studies
conducted in Japan (5.7%) and the United Kingdom (6%).16,41
This may be explained by the higher median age in these
studies and the lower risk of macrovascular disease in the
Black African population in South Africa.42
Strengths of the study include access to complete clinical and
laboratory data on all patients due to the electronic health
record system as well the fact that all patients had laboratory
investigations at each clinic visit using a set clinic protocol. In
addition, the clinic population is broadly representative of the
population from the entire province of KwaZulu-Natal.
The study had several limitations, including the relatively small
number of patients in the individual follow-up group as well
as the fact that mortality was not evaluated, and patients who
died during the study period were not included in the patient-
based analysis; this may have impacted on the findings on gly-
caemic parameters and complication rates.
Conclusion
Patients with T1D attending a tertiary diabetes clinic in South
Africa showed a significant improvement in glycaemic control
over a 10-year period on an individual basis, but not on a
whole-clinic basis. Overall glycaemic control fell short of rec-
ommended targets. Significant predictive risk factors for new
retinopathy development included diabetes duration and dias-
tolic blood pressure, while a positive anti-GAD was protective.
Our results indicate a need for intensified efforts to achieve
and maintain targets for both glycaemic and non-glycaemic par-
ameters in patients with T1D.
Disclosure statement – No potential conflict of interest was
reported by the author(s).
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